NCT04031729View on ClinicalTrials.gov

Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 12, 2019

Primary Completion Date

February 23, 2023

Study Completion Date

February 23, 2023

Conditions
Nonalcoholic Fatty LiverNonalcoholic Steatohepatitis
Interventions
DRUG

Aspirin 81 mg

Aspirin 81mg tablets will be given once daily, for the duration of the clinical trial.

DRUG

Placebo oral tablet

Identical, blinded placebo tablets will be given once daily, for the duration of the clinical trial.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

Massachusetts General Hospital

OTHER

NCT04031729 - Aspirin for the Treatment of Nonalcoholic Fatty Liver Disease | Biotech Hunter | Biotech Hunter